Update on the diagnosis and therapy of distant metastases of differentiated thyroid carcinoma

Minerva Endocrinologica

Volumn 33, Issue 4, 2008, Pages 313-327

  Zanotti Fregonara, P ^a   Hindie E ^b   Faugeron, I ^b   Moretti, J L ^b   Ravasi, L ^a   Rubello, D ^c   Toubert, M E ^b  

^a SERVICE HOSPITALIER FRÉDÉRIC JOLIOT   (France)

^b SAINT LOUIS HOSPITAL   (France)

^c VENETO INSTITUTE OF ONCOLOGY IOV IRCCS   (Italy)

Author keywords

Neoplasm metastasis, therapy; Radiotherapy; Thyroid neoplasms

Indexed keywords

B RAF KINASE; BEVACIZUMAB; CETUXIMAB; CYCLOOXYGENASE 2 INHIBITOR; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIRUBICIN; FLUOROURACIL; FOLINIC ACID; HISTONE DEACETYLASE INHIBITOR; IMATINIB; IRINOTECAN; LITHIUM; MITOGEN ACTIVATED PROTEIN KINASE; PLATELET DERIVED GROWTH FACTOR; RADIOACTIVE IODINE; RAS PROTEIN; RETINOID X RECEPTOR; RETINOL; THALIDOMIDE; THYROTROPIN; VASCULOTROPIN; ANTINEOPLASTIC AGENT;

AGE; ANGIOGENESIS; ASPIRATION BIOPSY; BONE METASTASIS; BONE SCINTISCANNING; CHRONIC MYELOID LEUKEMIA; COMPUTER ASSISTED TOMOGRAPHY; DISEASE COURSE; DISEASE FREE INTERVAL; DISTANT METASTASIS; FOLLICULAR CARCINOMA; GENE EXPRESSION; HUMAN; HYPOTHYROIDISM; LUNG METASTASIS; LYMPH NODE; MORTALITY; NUCLEAR MAGNETIC RESONANCE IMAGING; PAPILLARY CARCINOMA; PROGNOSIS; RADIOTHERAPY; REVIEW; SIGNAL TRANSDUCTION; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; SURVIVAL RATE; THORAX RADIOGRAPHY; THYROID CANCER; THYROID CARCINOMA; THYROIDECTOMY; ADENOCARCINOMA; LYMPH NODE METASTASIS; METASTASIS; SURVIVAL; THYROID TUMOR; TREATMENT OUTCOME;

ADENOCARCINOMA, FOLLICULAR; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; HUMANS; IODINE RADIOISOTOPES; LYMPHATIC METASTASIS; PROGNOSIS; SURVIVAL ANALYSIS; THYROID NEOPLASMS; THYROIDECTOMY; TREATMENT OUTCOME;

EID: 60849100251     PISSN: 03911977     EISSN: 18271634     Source Type: Journal    
DOI: None     Document Type: Review

References (99)

1. Davies L, Welch HG. Increasing incidence of thyroid cancer in the United States, 1973-2002. JAMA 2006;295:2164-7.
2. Hundahl SA, Fleming ID, Fremgen AM, Menck HR. A National Cancer Data Base report on 53 856 cases of thyroid carcinoma treated in the U.S., 1985-1995. Cancer 1998;83:2638-48.
3. Schlumberger MJ. Papillary and follicular thyroid carcinoma. N Engl J Med 1998;338:297-306.
4. Clark JR, Lai P, Hall F, Borglund A, Eski S, Freeman JL. Variables predicting distant metastases in thyroid cancer. Laryngoscope 2005;115:661-7.
5. Casara D, Rubello D, Saladini G, Masarotto G, Favero A, Girelli ME et al. Different features of pulmonary metastases in differentiated thyroid cancer: natural history and multivariate statistical analysis of prognostic variables. J Nucl Med 1993,34:1626-31.
6. Kitamura Y, Shimizu K, Nagahama M, Sugino K, Ozaki O, Mimura T et al. Immediate causes of death in thyroid carcinoma: clinicopathological analysis of 161 fatal cases. J Clin Endocrinol Metab 1999;84:4043-9.
7. Lin JD, Huang MJ, Juang JH, Chao TC, Huang BY, Chen KW et al. Factors related to the survival of papillary and follicular thyroid carcinoma patients with distant metastases. Thyroid 1999;9:1227-35.
8. Beasley NJ, Walfish PG, Witterick I, Freeman JL. Cause of death in patients with well-differentiated thyroid carcinoma. Laryngoscope 2001;111:989-91.
9. Melliere D, Hindie E, Becquemin JP, Desgranges P, Allaire E, Geachan E. Differentiated thyroid carcinoma how to improve the long-term results? Twenty-five-year outcomes of 850 patients. Bull Acad Natl Med 2006;190:89-106.
10. Cooper DS, Doherty GM, Haugen BR, Kloos RT, Lee SL, Mandel SJ et al. Management guidelines for patients with thyroid nodules and differentiated thyroid cancer. Thyroid 2006;16:109-42.
11. Pacini F, Schlumberger M, Dralle H, Elisei R, Smit JW, Wiersinga W; European Thyroid Cancer Taskforce. European consensus for the management of patients with differentiated thyroid carcinoma of the follicular epithelium. Eur J Endocrinol 2006;154:787-803. (Pubitemid 43997716)
12. Muresan MM, Olivier P, Leclère J, Sirveaux F, Brunaud L, Klein M et al. Bone metastases from differentiated thyroid carcinoma. Endocr Relat Cancer 2008;15:37-49. (Pubitemid 351449726)
13. Durante C, Haddy N, Baudin E, Leboulleux S, Hartl D, Travagli JP et al. Long-term outcome of 444 patients with distant metastases from papillary and follicular thyroid carcinoma: benefits and limits of radioiodine therapy. J Clin Endocrinol Metab 2006;91:2892-9.
14. Jarzab B, Handkiewicz-Junak D, Wloch J. Juvenile differentiated thyroid carcinoma and the role of radioiodine in its treatment: a qualitative review. Endocr Relat Cancer 2005;12:773-803.
15. Akslen LA, Myking AO, Salvesen H, Varhaug JE. Prognostic importance of various clinicopathological features in papillary thyroid carcinoma. Eur J Cancer 1992;29A:44-51.
16. Toniato A, Boschin I, Casara D, Mazzarotto R, Rubello D, Pelizzo M. Papillary thyroid carcinoma: factors influencing recurrence and survival. Ann Surg Oncol 2008;15:1518-22.
17. Pelikan DM, Lion HL, Hermans J, Goslings BM. The role of radioactive iodine in the treatment of advanced differentiated thyroid carcinoma. Clin Endocrinol (Oxf) 1997;47:713-20. (Pubitemid 28046560)
18. Albareda M, Puig-Domingo M, Wengrowicz S, Soldevila J, Matias-Guiu X, Caballero A et al. Clinical forms of presentation and evolution of diffuse sclerosing variant of papillary carcinoma and insular variant of follicular carcinoma of the thyroid. Thyroid 1998;8:385-91.
19. Mazzaferri EL, Young RL. Papillary thyroid carcinoma: a 10 year follow-up report of the impact of therapy in 576 patients. Am J Med 1981;70:511-8.
20. Segal K, Shpitzer T, Hazan A, Bachar G, Marshak G, Popovtzer A. Invasive well-differentiated thyroid carcinoma: effect of treatment modalities on outcome. Otolaryngol Head Neck Surg 2006;34:819-22.
21. Leboulleux S, Rubino C, Baudin E, Caillou B, Hartl DM, Bidart JM et al. Prognostic factors for persistent or recurrent disease of papillary thyroid carcinoma with neck lymph node metastases and/or tumor extension beyond the thyroid capsule at initial diagnosis. J Clin Endocrinol Metab 2005;90:5723-9.
22. Mazzaferri EL, Kloos RT. Clinical review 128: Current approaches to primary therapy for papillary and follicular thyroid cancer. J Clin Endocrinol Metab 2001;86:1447-63.
23. Rouxel A, Hejblum G, Bernier MO, Boëlle PY, Ménégaux F, Mansour G et al. Prognostic factors associated with the survival of patients developing locoregional recurrences of differentiated thyroid carcinomas. J Clin Endocrinol Metab 2004;89:5362-8.
24. Mazzaferri EL, Jhiang SM. Long-term impact of initial surgical and medical therapy on papillary and follicular thyroid cancer. Am J Med 1994;97:418-28.
25. Chen KT, Lin JD, Chao TC, Hsueh C, Chang CA, Weng HF et al. Identifying differentially expressed genes associated with metastasis of follicular thyroid cancer by cDNA expression array. Thyroid 2001;11:41-6.
26. Wexler JA, Sharretts J. Thyroid and bone. Endocrinol Metab Clin North Am 2007;36:673-705.
27. Kebebew E, Weng J, Bauer J, Ranvier G, Clark OH, Duh QY et al. The prevalence and prognostic value of BRAF mutation in thyroid cancer. Ann Surg 2007;246:466-70.
28. Consensus conference: management of differentiated cancers of the thyroid vesicular structure. Ann Endocrinol (Paris) 2007;68(Suppl 2):S53-6.
29. Zanotti-Fregonara P, Khoury A, Duron F, Keller I, Christin-Maître S, Kiffel T et al. Which thyroid cancer patients need periodic stimulation tests? Eur J Nucl Med Mol Imaging 2007;34:541-6.
30. Rubello D, Pelizzo MR, Casara D, Piotto A, Toniato A, Fig L et al. Radio-guided surgery for non-131I-avid thyroid cancer. Thyroid 2006;16:1105-11.
31. 99mTc-sestamibi radio-guided surgery of loco-regional 131Iodine-negative recurrent thyroid cancer. Eur J Surg Oncol 2007;33:902-6.
32. Brierley JD, Tsang RW. External-beam radiation therapy in the treatment of differentiated thyroid cancer. Semin Surg Oncol 1999;16:42-9.
33. Vassilopoulou-Sellin R, Schultz PN, Haynie TP. Clinical outcome of patients with papillary thyroid carcinoma who have recurrence after initial radioactive iodine therapy. Cancer 1996;78:493-501.
34. Baudin E, Schlumberger M. New therapeutic approaches for metastatic thyroid carcinoma. Lancet Oncol 2007;8:148-56.
35. Dinneen SF, Valimaki MJ, Bergstralh EJ, Goellner JR, Gorman CA, Hay ID. Distant metastases in papillary thyroid carcinoma: 100 cases observed at one institution during 5 decades. J Clin Endocrinol Metab 1995;80:2041-5.
36. Ruegemer JJ, Hay ID, Bergstralh EJ, Ryan JJ, Offord KP, Gorman CA. Distant metastases in differentiated thyroid carcinoma. A multivariate analysis of prognosis variables. J Clin Endocrinol Metab 1988;67:501-8.
37. Haq M, Harmer C. Differentiated thyroid carcinoma with distant metastases at presentation: prognostic factors and outcome. Clin Endocrinol (Oxf) 2005;63:87-93. (Pubitemid 40966408)
38. Schlumberger M, Challeton C, de Vathaire F, Travagli JP, Gardet P, Lumbroso JD et al. Radioactive iodine treatment and external radiotherapy for lung and bone metastases from thyroid carcinoma. J Nucl Med 1996;37:598-605. (Pubitemid 126618447)
39. Sampson E, Brierley JD, Le LW, Rotstein L, Tsang RW. Clinical management and outcome of papillary and follicular (differentiated) thyroid cancer presenting with distant metastasis at diagnosis. Cancer 2007;110:1451-6.
40. La Quaglia MP, Black T, Holcomb GW 3rd, Sklar C, Azizkhan RG, Haase GM et al. Differentiated thyroid cancer: clinical characteristics, treatment, and outcome in patients under 21 years of age who present with distant metastases. A report from the Surgical Discipline Committee of the Children's Cancer Group. J Pediatr Surg 2000;35:955-9.
41. Samuel AM, Rajashekharrao B, Shah DH. Pulmonary metastases in children and adolescents with well-differentiated thyroid cancer. J Nucl Med 1998;39:1531-6.
42. Hindié E, Zanotti-Fregonara P, Keller I, Duron F, Devaux JY, Calzada-Nocaudie M et al. Bone metastases of differentiated thyroid cancer: impact of early 131I-based detection on outcome. Endocr Relat Cancer 2007;14:799-807. (Pubitemid 350074068)
43. Pacini F, Cetani F, Miccoli P, Mancusi F, Ceccarelli C, Lippi F et al. Outcome of 309 patients with metastatic thyroid carcinoma treated with radioiodine. World J Surg 1994;18:600-4.
44. Bernier MO, Leenhardt L, Hoang C, Aurengo A, Mary JY, Menegaux F et al. Survival and therapeutic modalities in patients with bone metastases of differentiated thyroid carcinomas. J Clin Endocrinol Metab 2001;86:1568-73.
45. Niederle B, Roka R, Schemper M, Fritsch A, Weissel M, Ramach W. Surgical treatment of distant metastases in differentiated thyroid cancer: indication and results. Surgery 1986;100:1088-97.
46. Pittas AG, Adler M, Fazzari M, Tickoo S, Rosai J, Larson SM et al. Bone metastases from thyroid carcinoma: clinical characteristics and prognostic variables in one hundred forty-six patients. Thyroid 2000;10:261-8.
47. Zettinig G, Fueger BJ, Passier C, Kaserer K, Pirich C, Dudczak R et al. Long-term follow-up of patients with bone metastases from differentiated thyroid carcinoma surgery or conventional therapy? Clin Endocrinol (Oxf) 2002;56:377-82.
48. Spencer CA, Lopresti JS. Measuring thyroglobulin and thyroglobulin autoantibody in patients with differentiated thyroid cancer. Nat Clin Pract Endocrinol Metab 2008;4:223-33.
49. Wartofsky L, Sherman SI, Gopal J, Schlumberger M, Hay ID. The use of radioactive iodine in patients with papillary and follicular thyroid cancer. J Clin Endocrinol Metab 1998;83:4195-203.
50. Hindié E, Melliere D, Lange F, Hallaj I, de Labriolle-Vaylet C, Jeanguillaume C et al. Functioning pulmonary metastases of thyroid cancer: does radioiodine influence the prognosis? Eur J Nucl Med Mol Imaging 2003;30:974-81.
51. Schlumberger M, Arcangioli O, Piekarski JD, Tubiana M, Parmentier C. Detection and treatment of lung metastases of differentiated thyroid carcinoma in patients with normal chest X-rays. J Nucl Med 1988;29:1790-4.
52. Grünwald F, Kälicke T, Feine U, Lietzenmayer R, Scheidhauer K, Dietlein M et al. Fluorine-18 fluorodeoxyglucose positron emission tomography in thyroid cancer: results of a multicentre study. Eur J Nucl Med 1999;26:1547-52.
53. Hindié E, Zanotti-Fregonara P, Duron F, Keller I, Bouchard P, Devaux JY. Should "low-risk" thyroid cancer patients with residual thyroglobulin be re-treated with iodine 131? Clin Endocrinol (Oxf) 2007;66:329-34.
54. Feine U, Lietzenmayer R, Hanke JP, Held J, Wöhrle H, Müller-Schauenburg W. Fluorine-18-FDG and iodine-131-iodide uptake in thyroid cancer. J Nucl Med 1996;37:1468-72.
55. Robbins RJ, Wan Q, Grewal RK, Reibke R, Gonen M, Strauss HW et al. Real-time prognosis for metastatic thyroid carcinoma based on 2-[18F]fluoro-2-deoxy-D-glucose-positron emission tomography scanning. J Clin Endocrinol Metab 2006;91:498-505.
56. Maxon HR, Thomas SR, Hertzberg VS, Kereiakes JG, Chen IW, Sperling MI et al. Relation between effective radiation dose and outcome of radioiodine therapy for thyroid cancer. N Engl J Med 1983;309:937-41.
57. Luster M, Lippi F, Jarzab B, Perros P, Lassmann M, Reiners C et al. rhTSH-aided radioiodine ablation and treatment of differentiated thyroid carcinoma: a comprehensive review. Endocr Relat Cancer 2005; 12:49-64.
58. Zanotti-Fregonara P, Toubert ME, Taieb D, Ravasi L, Rubello D, Hindie E. Overview on the use of recombinant human thyrotropin in thyroid cancer of follicular cell origin. Minerva Endocrinol 2008;33:53-65.
59. Sugitani I, Fujimoto Y, Yamamoto N. Papillary thyroid carcinoma with distant metastases: survival predictors and the importance of local control. Surgery 2008;143:35-42. (Pubitemid 350266026)
60. Pacini F, Lippi F, Formica N, Elisei R, Anelli S, Ceccarelli C et al. Therapeutic doses of iodine-131 reveal undiagnosed metastases in thyroid cancer patients with detectable serum thyroglobulin levels. J Nucl Med 1987;28:1888-91.
61. Smit JWA, Vielvoye GJ, Goslings BM. Embolization for vertebral metastases of follicular thyroid carcinoma. J Clin Endocrinol Metab 2000;85:989-94.
62. Toyota N, Naito A, Kakizawa H, Hieda M, Hirai N, Tachikake T et al. Radiofrequency ablation therapy combined with cementoplasty for painful bone metastases: initial experience. Cardiovasc Intervent Radiol 2005;28:578-83.
63. Vitale G, Fonderico F, Martignetti A, Caraglia M, Ciccarelli A, Nuzzo V et al. Pamidronate improves the quality of life and induces clinical remission of bone metastases in patients with thyroid cancer. Br J Cancer 2001;84:1586-90.
64. Rubino C, de Vathaire F, Dottorini ME, Hall P, Schvartz C, Couette JE et al. Second primary malignancies in thyroid cancer patients. Br J Cancer 2003;89:1638-44.
65. Brown AP, Chen J, Hitchcock YJ, Szabo A, Shrieve DC, Tward JD. The risk of second primary malignancies up to three decades after the treatment of differentiated thyroid cancer. J Clin Endocrinol Metab. 2008;93:504-15
66. 131I in male patients with thyroid carcinoma. Arch Androl. 2005;51:171-5.
67. Garsi JP, Schlumberger M, Rubino C, Ricard M, Labbé M, Ceccarelli C et al. Therapeutic Administration of 131I for Differentiated Thyroid Cancer: Radiation Dose to Ovaries and Outcome of Pregnancies. J Nucl Med J Nucl Med 2008;49:845-52.
68. Champion C, Zanotti-Fregonara P, Hindié E. CELL-DOSE: a Monte Carlo code to assess electron dose distribution - S values for 131I in spheres of various sizes. J Nucl Med 2008;49:151-7.
69. Shimaoka K, Schoenfeld DA, DeWys WD, Creech RH, DeConti R. A randomized trial of doxorubicin versus doxorubicin plus cisplatin in patients with advanced thyroid carcinoma. Cancer 1985;56:2155-60.
70. De Besi P, Busnardo B, Toso S, Girelli ME, Nacamulli D, Simioni N et al. Combined chemotherapy with bleomycin, adriamycin, and platinum in advanced thyroid cancer. J Endocrinol Invest 1991;14:475-80.
71. Santini F, Bottici V, Elisei R, Montanelli L, Mazzeo S, Basolo F et al. Cytotoxic effects of carboplatinum and epirubicin in the setting of an elevated serum thyrotropin for advanced poorly differentiated thyroid cancer. J Clin Endocrinol Metab 2002;87:4160-5.
72. Sarlis NJ, Gourgiotis L, Guthrie LC, Galen B, Skarulis MC, Shawker TH et al. In-111 DTPA-octreotide scintigraphy for disease detection in metastatic thyroid cancer: comparison with F-18 FDG positron emission tomography and extensive conventional radiographic imaging. Clin Nucl Med 2003;28:208-17.
73. Teunissen JJ, Kwekkeboom DJ, Kooij PP, Bakker WH, Krenning EP. Peptide receptor radionuclide therapy for non-radioiodine-avid differentiated thyroid carcinoma. J Nucl Med 2005;46(Suppl 1):107S-14S.
74. Koong SS, Reynolds JC, Movius EG, Keenan AM, Ain KB, Lakshmanan MC et al. Lithium as a potential adjuvant to 131I therapy of metastatic, well differentiated thyroid carcinoma. J Clin Endocrinol Metab 1999;84:912-6.
75. Liu YY, van der Pluijm G, Karperien M, Stokkel MP, Pereira AM, Morreau J et al. Lithium as adjuvant to radioiodine therapy in differentiated thyroid carcinoma: clinical and in vitro studies. Clin Endocrinol (Oxf) 2006;64:617-24.
76. Schmutzler C, Brtko J, Winzer R, Jakobs TC, Meissner-Weigl J, Simon D et al. Functional retinoid and thyroid hormone receptors in human thyroid-carcinoma cell lines and tissues. Int J Cancer 1998;76:368-76.
77. Kurebayashi J, Tanaka K, Otsuki T, Moriya T, Kunisue H, Uno M et al. All-trans-retinoic acid modulates expression levels of thyroglobulin and cytokines in a new human poorly differentiated papillary thyroid carcinoma cell line, KTC-1. J Clin Endocrinol Metab 2000;85:2889-96.
78. Gruning T, Tiepolt C, Zophel K, Bredow J, Kropp J, Franke WG. Retinoic acid for redifferentiation of thyroid cancer - does it hold its promise? Eur J Endocrinol 2003;148:395-402.
79. Grunwald F, Menzel C, Bender H, Palmedo H, Otte R, Fimmers R et al. Redifferentiation therapy-induced radioiodine uptake in thyroid cancer. J Nucl Med 1998;39:1903-6.
80. Simon D, Körber C, Krausch M, Segering J, Groth P, Görges R et al. Clinical impact of retinoids in redifferentiation therapy of advanced thyroid cancer: final results of a pilot study. Eur J Nucl Med Mol Imaging 2002;29:775-82.
81. Toubert ME, Darsin D, Cassinat B, Tenenbaum F, Corone C, Rain JD et al. Redifferentiation therapy with retinoids for radioiodine negative thyroid cancer patients. Eur J Nucl Med Mol Imaging 2003;30:O106. p S172.
82. Courbon F, Zerdoud S, Bastie D, Archambaud F, Hoff M, Eche N et al. Defective efficacy of retinoic acid treatment in patients with metastatic thyroid carcinoma. Thyroid 2006;16:1025-31.
83. Liu YY, Stokkel MP, Morreau HA, Pereira AM, Romijn JA, Smit JW. Radioiodine therapy after pretreatment with bexarotene for metastases of differentiated thyroid carcinoma. Clin Endocrinol (Oxf) 2008;68:605-9.
84. Zhang Y, Jia S, Liu Y, Li B, Wang Z, Lu H et al. A clinical study of all-trans-retinoid-induced differentiation therapy of advanced thyroid cancer. Nucl Med Commun 2007;28:251-5.
85. Cras A, Darsin-Bettinger D, Balitrand N, Cassinat B, Soulie A, Toubert ME et al. Epigenetic patterns of the retinoic acid receptor beta2 promoter in retinoic acid-resistant thyroid cancer cells. Oncogene 2007;26:4018-24.
86. Riesco-Eizaguirre G, Santisteban P. New insights in thyroid follicular cell biology and its impact in thyroid cancer therapy. Endocr Relat Cancer 2007;14:957-77.
87. Krause DS, Van Etten RA. Tyrosine kinases as targets for cancer therapy. N Engl J Med 2005;353:172-87.
88. Fagin JA How thyroid tumors start and why it matters: kinase mutants as targets for solid cancer pharmacotherapy. J Endocrinol 2004;183:249-56.
89. O'Brien SG, Guilhot F, Larson RA, Gathmann I, Baccarani M, Cervantes F et al. Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med 2003;348:994-1004. (Pubitemid 36302244)
90. Pennell NA, Daniels GH, Haddad RI, Ross DS, Evans T, Wirth LJ et al. A Phase II Study of Gefitinib in Patients with Advanced Thyroid Cancer. Thyroid 2008;18:317-23.
91. Pacini F. Where Do We Stand with Targeted Therapy of Refractory Thyroid Cancer?-Utility of RECIST Criteria. Thyroid 2008;18:279-80.
92. Sherman I, Schlumberger MJ, Droz J, Hoffmann M, Wirth L, Bastholt L et al. Initial results from a phase II trial of motesanib diphosphate (AMG 706) in patients with differentiated thyroid cancer (DTC). 2007 ASCO Annual Meeting Proceedings Part I. Vol. 25, No. 18S (June 20 Supplement), 2007:6017.
93. Kloos R, Ringel M, Knopp M, Heverhagen J, Rittenberry J, Weldy L et al. Significant clinical and biologic activity of RAF/VEGF-R kinase inhibitor BAY 43-9006 in patients with metastatic papillary thyroid carcinoma (PTC): Updated results of a phase II study. 2006 ASCO Annual Meeting Proceedings (Post-Meeting Edition). Vol. 24, No. 18S (June 20 Supplement), 2006:5534.
94. Gupta V, Puttaswamy K, Lassoued W, Redlinger M, Ransone K, Gold K et al. Sorafenib targets BRAF and VEGFR in metastatic thyroid carcinoma. 2007 ASCO Annual Meeting Proceedings (Post-Meeting Edition). Vol 25, No 18S (June 20 Supplement), 2007:6019.
95. Cohen EE, Vokes EE, Rosen LS, Kies MS, Forastiere AA, Worden FP et al. A phase II study of axitinib (AG-013736 [AG]) in patients (pts) with advanced thyroid cancers 2007 ASCO Annual Meeting Proceedings Part I. Vol 25, No. 18S (June 20 Supplement), 2007:6008.
96. Ain KB, Lee C, Williams KD. Phase II trial of thalidomide for therapy of radioiodine-unresponsive and rapidly progressive thyroid carcinomas. Thyroid 2007;17:663-70.
97. Mrozek E, Kloos RT, Ringel MD, Kresty L, Snider P, Arbogast D et al. Phase II study of celecoxib in metastatic differentiated thyroid carcinoma. J Clin Endocrinol Metab 2006;91:2201-4.
98. O'Reilly MS. Radiation combined with antiangiogenic and antivascular agents. Semin Radiat Oncol 2006;16:45-50.
99. Hurwitz H, Fehrenbacher L, Novotny W, Cartwright T, Hainsworth J, Heim W et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 2004;350:2335-42.